Filed revenue acceleration
Active · now 10.526315789473696%TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
Free trial
Analyze this stock with AI
Ask AI to research recent events and build a visual report.
Tell your AI:
“Help me set up FinLab and analyze ELAN Elanco Animal Health Incorporated: https://finlab.finance/en/setup?stock=ELAN”
ELAN
Elanco Animal Health Incorporated Healthcare As of 2026-06-18
Quality Above avg
Valuation Cheaper
Risk High vol
Active signals Active Filed revenue acceleration
24.22 Close (USD)
-2.73% 60-day
- Quality is above average. Operating margin sits near the 55th percentile. TTM ROE is about -3.7%.
- Valuation is cheaper than most peers. TTM P/E is in the 6th percentile, lower than most liquid US common stocks.
- Recent volatility is elevated. 60-day annualized volatility is in the 72th percentile. Average 20-day dollar volume is about $148.3M.
- Signals are active now. Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.
Factor profile
Factor radar Good Valuation
64Valuation
Indicators in this group are ranked by market percentile; lower valuation and volatility are better.
TTM P/E -49.65
Price / book 1.85
Free-cash-flow yield (%) 2.61
Historical evidence
Signals active now
Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.
Market-wide momentum baseline
Across 94,737 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.40%, a 58.3% positive-return rate, and +3.10 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
52-week adjusted-price high
PendingAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
11 times historically; 60-day forward avg -3.48%, win rate 27.3%, beating the market by -7.99 pts on average.
Top-quintile 6-month momentum
PendingThe stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
9 times historically; 60-day forward avg +13.63%, win rate 55.6%, beating the market by +5.59 pts on average.
EPS surprise beat
PendingReported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.
26 times historically; 60-day forward avg +0.76%, win rate 48%, beating the market by -3.19 pts on average.
Free trial
Analyze this stock with AI
Ask AI to research recent events and build a visual report.
Tell your AI:
“Help me set up FinLab and analyze ELAN Elanco Animal Health Incorporated: https://finlab.finance/en/setup?stock=ELAN”
Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.